Drug Profile
Enaritide
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator APEPTICO Forschung und Entwicklung
- Developer APEPTICO Forschung und Entwicklung; University of Vienna
- Class Peptides
- Mechanism of Action Sodium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudohypoaldosteronism
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for research development in Pseudohypoaldosteronism in Austria (Inhalation, Powder)
- 02 Jan 2015 Early research in Pseudohypoaldosteronism in Austria (Inhalation)